Both in Pharmaceuticals
AnaptysBio vs UroGen Pharma
Over the past year ANAB returned +36.8% and URGN returned +45.1%; their daily moves had a correlation of 0.11.
ANAB +36.8% URGN +45.1%Growth of $1, one year, split-adjusted
| Metric | ANAB | URGN |
|---|---|---|
| Price | $47.51 | $28.74 |
| Market cap | $1.42B | $1.40B |
| Today | −0.46% | −16.45% |
| 1 month | −0.8% | −30.6% |
| 6 months | −29.5% | +9.5% |
| Year to date | −2.0% | +22.7% |
| 1 year | +31.8% | +39.4% |
| Revenue growth (YoY) | −8.0% | +199.2% |
| Gross margin | 100.0% | 90.9% |
| Net margin | −206.9% | −19.8% |
| P/E (TTM) | — | — |
| Price / sales | 6.1× | 7.4× |
| Net cash | $286.5M | -$85.1M |
| Dividend yield | — | — |
| Volatility (60d) | 40.0% | 54.9% |
| Short % of float | 30.6% | 12.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).